Xeroderma PigmentosumPhase 2NCT05370235
A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V
A Phase 2 study testing Afamelanotide in people with Xeroderma Pigmentosum, run by Clinuvel Europe Limited at 2 sites in 2 countries.
Trial summary
The CUV152 study will evaluate the safety of afamelanotide in XP-C and XP-V patients, as well as the drug's ability to assist reparative processes following ultraviolet (UV) provoked DNA damage of the skin. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Xeroderma Pigmentosum
- What is being tested?
- Afamelanotide
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 6 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 28 Mar 2022to Dec 2024
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female patient with a molecular-genetically confirmed diagnosis of XP-C or XP-V;
- Aged 18-75 years.
Who cannot join
- Known allergy to afamelanotide or the polymer contained in the implant;
- Presence of severe hepatic disease or hepatic impairment;
- Renal impairment;
- Any other medical condition which may interfere with the study protocol;
- Existing melanoma;
- Female who is pregnant or lactating;
Show all 10Show fewer
- Females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures;
- Sexually active man with a partner of child-bearing potential who is not using adequate contraceptive measures;
- Use of any other prior and concomitant therapy which may interfere with the objective of the study;
- Participation in a clinical trial for an investigational agent.
Trial locations and contacts
2 sites in 2 countries.
2 sites in 2 countries
Belgium1 site, 1 recruiting
- Recruiting
CLINUVEL Investigational site
Clinuvel Investigational Site
Head of Clinical Operations, +441372860765, mail@clinuvel.com
Spain1 site, 1 recruiting
- Recruiting
CLINUVEL Investigational site
Clinuvel Investigational Site
Head of Clinical Operations, +441372860765, mail@clinuvel.com
About this study
Official title: A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients With Xeroderma Pigmentosum C and V (XPC and XPV)
The CUV152 study will evaluate the safety of afamelanotide in XP-C and XP-V patients, as well as the drug's ability to assist reparative processes following ultraviolet (UV) provoked DNA damage of the skin. It will assess whether SCENESSE® increases the amount of UV light needed to cause DNA damage of skin cells, as well as the extent of skin repair before and after treatment.
- Conditions
- Xeroderma Pigmentosum
- Being tested
- Afamelanotide
- Medical subject headings
- Xeroderma Pigmentosum
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AfamelanotideDrug
Patients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later.
| Study group | Role | What they receive |
|---|---|---|
| Afamelanotide | Experimental | Not described Receives: Drug: Afamelanotide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in minimal erythema dose (MED) in patients with XP-C.
MED is the lowest dose of UV light that causes reddening of the skin.
Measured: From baseline to day 76.
Change in MED in patients with XP-V.
MED is the lowest dose of UV light that causes reddening of the skin.
Measured: From baseline to day 76.
Secondary outcomes (14)
Changes in UV-induced DNA damage, as assessed by quantification of UV photoproduct levels in patients with XP-C.
Analysis of UV photoproducts from skin samples.
Measured: From baseline to day 76.
Changes in UV-induced DNA damage repair capacity, as assessed by quantification of DNA repair mechanisms in patients with XP-C.
Analysis of DNA repair mechanisms from skin samples.
Measured: From baseline to day 76.
Changes in UV-induced DNA damage, as assessed by quantification of UV photoproduct levels in patients with XP-V.
Analysis of UV photoproducts from skin samples.
Measured: From baseline to day 76.
Changes in UV-induced DNA damage repair capacity, as assessed by quantification of DNA repair mechanisms in patients with XP-V.
Analysis of DNA repair mechanisms from skin samples.
Measured: From baseline to day 76.
Change in skin disease severity in patients with XP-C (A).
The higher the score, the more severe the disease.
Measured: From baseline to day 76.
Change in skin disease severity in patients with XP-V (A)
The higher the score, the more severe the disease.
Measured: From baseline to day 76.
Change in skin disease severity in patients with XP-C (B).
The higher the score, the more severe the disease.
Measured: From baseline to day 76.
Change in skin disease severity in patients with XP-V (B).
The higher the score, the more severe the disease.
Measured: From baseline to day 76.
Change in skin disease severity in patients with XP-C (C).
The higher the score, the more severe the disease.
Measured: From baseline to day 76.
Change in skin disease severity in patients with XP-V (C).
The higher the score, the more severe the disease.
Measured: From baseline to day 76.
Change in quality of life assessed by a disease specific tool (A) in patients with XP-C.
Higher scores represent worse health-related quality of life.
Measured: From baseline to day 76.
Change in quality of life assessed by a disease specific tool (A) in patients with XP-V.
Higher scores represent worse health-related quality of life.
Measured: From baseline to day 76.
Change in quality of life assessed by a validated global quality of life tool (B) in patients with XP-C.
Score calculated in impairment percentages, with higher numbers indicating greater impaired quality of life.
Measured: From baseline to day 76.
Change in quality of life assessed by a validated global quality of life tool (B) in patients with XP-V.
Score calculated in impairment percentages, with higher numbers indicating greater impaired quality of life.
Measured: From baseline to day 76.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2022
- Study start28 Mar 2022
- Primary completionJun 2024 (estimated)
- Study completionDec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Xeroderma PigmentosumStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 6 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Clinuvel Europe Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05370235
- Sponsor's protocol ID
- CUV152
- Status last verified
- Sep 2023
- First submitted
- 21 Apr 2022
- Last updated
- 21 Sep 2023
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients With Xeroderma Pigmentosum C and V (XPC and XPV)
- ClinicalTrials.gov ID
- NCT05370235
- Acronym / sponsor ID
- CUV152
- Conditions
- Xeroderma Pigmentosum
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 6 participants (estimated)
- Lead sponsor
- Clinuvel Europe LimitedIndustry (pharma, biotech, devices)
- Study start
- 28 Mar 2022 (actual)
- Primary completion
- Jun 2024 (estimated)
- Study completion
- Dec 2024 (estimated)
- First posted
- 11 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The CUV152 study will evaluate the safety of afamelanotide in XP-C and XP-V patients, as well as the drug's ability to assist reparative processes following ultraviolet (UV) provoked DNA damage of the skin. It will assess whether SCENESSE® increases the amount of UV light needed to cause DNA damage of skin cells, as well as the extent of skin repair before and after treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Afamelanotide | Experimental | Drug: Afamelanotide |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Male or female patient with a molecular-genetically confirmed diagnosis of XP-C or XP-V;
- Aged 18-75 years.
Key exclusion criteria (10 listed)
- Known allergy to afamelanotide or the polymer contained in the implant;
- Presence of severe hepatic disease or hepatic impairment;
- Renal impairment;
- Any other medical condition which may interfere with the study protocol;
- Existing melanoma;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AfamelanotidePatients will receive afamelanotide every two weeks for twelve weeks and undergo a follow up visit 6 months later. | Drug | Afamelanotide |
Primary outcome
Change in minimal erythema dose (MED) in patients with XP-C.
Time frame: From baseline to day 76.
MED is the lowest dose of UV light that causes reddening of the skin.
Change in MED in patients with XP-V.
Time frame: From baseline to day 76.
MED is the lowest dose of UV light that causes reddening of the skin.
14 secondary outcomes
Changes in UV-induced DNA damage, as assessed by quantification of UV photoproduct levels in patients with XP-C.
Time frame: From baseline to day 76.
Changes in UV-induced DNA damage repair capacity, as assessed by quantification of DNA repair mechanisms in patients with XP-C.
Time frame: From baseline to day 76.
Changes in UV-induced DNA damage, as assessed by quantification of UV photoproduct levels in patients with XP-V.
Time frame: From baseline to day 76.
Changes in UV-induced DNA damage repair capacity, as assessed by quantification of DNA repair mechanisms in patients with XP-V.
Time frame: From baseline to day 76.
Change in skin disease severity in patients with XP-C (A).
Time frame: From baseline to day 76.
Change in skin disease severity in patients with XP-V (A)
Time frame: From baseline to day 76.
Change in skin disease severity in patients with XP-C (B).
Time frame: From baseline to day 76.
Change in skin disease severity in patients with XP-V (B).
Time frame: From baseline to day 76.
Change in skin disease severity in patients with XP-C (C).
Time frame: From baseline to day 76.
Change in skin disease severity in patients with XP-V (C).
Time frame: From baseline to day 76.
Change in quality of life assessed by a disease specific tool (A) in patients with XP-C.
Time frame: From baseline to day 76.
Change in quality of life assessed by a disease specific tool (A) in patients with XP-V.
Time frame: From baseline to day 76.
Change in quality of life assessed by a validated global quality of life tool (B) in patients with XP-C.
Time frame: From baseline to day 76.
Change in quality of life assessed by a validated global quality of life tool (B) in patients with XP-V.
Time frame: From baseline to day 76.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2023.
Related trials for Xeroderma Pigmentosum
RecruitingObservational study
Natural History Study for DNA Repair Disorders
DNA Repair Disorder, Cockayne Syndrome
RecruitingPhase 1/2
Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE)
Artemis (DCLRE1C ) Deficient Severe Combined Immunodeficiency
Enrolling by invitationObservational study
Reproductive Options in Inherited Skin Diseases
Ichthyosis, Palmoplantar Keratoses
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Afamelanotide in people with Xeroderma Pigmentosum, run by Clinuvel Europe Limited at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Belgium, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Head of Clinical Operations (+441372860765, mail@clinuvel.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in minimal erythema dose (MED) in patients with XP-C. (time frame: From baseline to day 76.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2023.